CraigL.SlingluffJr.MD

General Surgery • Charlottesville, VA

Surgical Oncology (Other than Breast)

Professor of Surgery, University VA School of Medicine

Join to view full profile

Dr. Slingluff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Slingluff's full profile

Already have an account?

Office
Dept of Surgery, University of Virginia PO Box 800709
Charlottesville, VA 22908
Phone+1 434-924-9311

Education & Training

Duke University HospitalResidency, Surgery, 1984 - 1991
University of Virginia School of MedicineClass of 1984

Certifications & Licensure

VA State Medical License 1991 - 2026
American Board of Surgery Surgery

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Fellow (FACS) American College of Surgeons

Clinical Trials

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1998 Apr 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Metastatic Melanoma Start of enrollment: 1996 Feb 01
Completed
Phase 1
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Start of enrollment: 2005 May 09
Completed
Phase 2
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Start of enrollment: 2003 Sep 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2002 Aug 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Start of enrollment: 2003 Jul 01
Completed
Phase 1, Phase 2
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Start of enrollment: 2005 Mar 01
Completed
Phase 1, Phase 2
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma Start of enrollment: 2004 Nov 04
Completed
Phase 1
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma Start of enrollment: 2008 Jan 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Advanced Melanoma Start of enrollment: 2008 May 01
Completed
Phase 1
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma Start of enrollment: 2000 May 01
Completed
Not Applicable
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38 Start of enrollment: 2004 Jun 01
Completed
Not Applicable
A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma Start of enrollment: 2008 Aug 01
Completed
Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma Start of enrollment: 1999 Nov 01
Completed
Phase 2
Pilot Study of Infrared Imaging of Cutaneous Melanoma Start of enrollment: 2008 Mar 01
Completed
Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma Start of enrollment: 2009 Nov 01
Terminated
Phase 1
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma Start of enrollment: 2011 Jan 01
Completed
Phase 1
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI Start of enrollment: 2011 Jun 01
Completed
Early Phase 1
Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma Start of enrollment: 2011 Mar 01
Completed
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Start of enrollment: 2012 May 01
Terminated
Phase 3
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients Start of enrollment: 2012 Oct 01
Completed
Phase 1
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2014 Jan 24
Terminated
Phase 1
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies Start of enrollment: 2013 May 01
Completed
Phase 1
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2013 Sep 13
Completed
Phase 2
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Start of enrollment: 2016 Dec 28
Completed
Phase 1, Phase 2
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma Start of enrollment: 2018 Nov 13
Completed
Phase 1, Phase 2
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Start of enrollment: 2020 Sep 28
Active, not recruiting
Phase 1, Phase 2
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Start of enrollment: 2019 Nov 21
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.
Lestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, Andressa Dias Costa, Matthew H G Katz
Clinical Cancer Research. 2024-02-01
6 citations
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectabl...
Matthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin
Journal for Immunotherapy of Cancer. 2023-12-01
1 citations
A Step Toward Personalized Surgical Decision Making: Machine Learning Predicts 1 Versus Numerous Melanoma Lymph Node Metastases Using RNA-sequencing.
Max O Meneveau, Rick D Vavolizza, Anwaruddin Mohammad, Pankaj Kumar, Joseph T Manderfield
Annals of Surgery. 2023-09-01

Lectures

Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

UVA Health Launches World's 1st Ultrasound Immunotherapy Cancer CenterMay 11th, 2022
World’s First Focused Ultrasound Cancer Immunotherapy Center Will Be at UVAMay 11th, 2022
Q&A: Cancer Death Rates Are Falling Nationally. Here’s What’s Happening at UVAJanuary 10th, 2020
Join now to see all

Grant Support

Postdoctoral Training Grant For MDS In Surgical Oncology ResearchNational Cancer Institute2011
Melanoma Vaccines Using Mhc-Associated PeptidesNational Cancer Institute2002–2011
Phase 2: CCI-779 In Combination With Bevacizumab In Stage III Or IV MelanomaNational Center For Research Resources2010
Intratumoral Interferon Gamma During Vaccination In Metastatic MelanomaNational Center For Research Resources2010
A Multipeptide Vaccine In Melanoma Patients With Evaluation Of Injection SiteNational Center For Research Resources2009–2010
Clinical Trial: A Phase II Trial Of Vaccination With Peptides For Patients WithNational Center For Research Resources2008–2010
Tissue Procurement FacilityNational Cancer Institute2006–2010
Multi-Peptide Vaccine Administered With Cyclophosphamide For High-Risk MelanomaNational Cancer Institute2006–2010
Clinical Trial: Evaluation Of Cyclophosphamide With Peptide Vaccines In ParticipNational Center For Research Resources2009
Clinical Trial: Phase 2: CCI-779 In Combination With Bevacizumab In Stage III OrNational Center For Research Resources2008–2009
Multi-Epitope Melanoma Vaccines For CD4 And CD8 T-CellsNational Cancer Institute2005–2009
Clinical Trial: Effects Of Local GM-CSF In-Adjuvant On Dendritic Cells In MelanoNational Center For Research Resources2008
Targeted Molecular Therapeutics For Melanoma: CCI-779 And BevacizumabNational Cancer Institute2007–2008
Evaluation Of Cyclophosphamide With Peptide Vaccines In Participants W/MelanomaNational Center For Research Resources2006–2008
Leukapheresis Collection Of Wbc?S From Normals And Participants With CancerNational Center For Research Resources2007
A Phase II Trial Of Vaccination With Peptides For Patients With MelanomaNational Center For Research Resources2006–2007
Transdermal Adjuvant Administration Of Peptide-Based Vaccine, High-Risk MelanomaNational Center For Research Resources2005–2007
Synthetic Helper Peptide Vaccines For Patients With Stage IV MelanomaNational Center For Research Resources2004–2007
Efficacy Of A Melanoma Peptide Vaccine In Patients With Advanced MelanomaNational Center For Research Resources2005–2006
Effects Of Local GM-CSF In-Adjuvant On Dendritic Cells In Melanoma PatientsNational Center For Research Resources2005–2006
Effect Of GM-CSF And Vaccine Site Number On Immunization With Melanoma PeptidesNational Center For Research Resources2004–2006
Peptide Vaccine For Patients With Advanced MelanomaNational Center For Research Resources2004–2005
Immunogenicity Of Vaccination With Multiple Synthetic Melanoma PeptidesNational Center For Research Resources2004
Efficacy Melanoma Peptide Vaccine For Advanced MelanomaNational Center For Research Resources2004
Vaccines With MHC Class Ii-Restricted Melanoma PeptidesNational Cancer Institute2003–2004
Multi-Epitope Melanoma Peptide Vaccination With GM-CSFNational Cancer Institute2003–2004
Vaccination W/ Melanoma Peptides On Dendritic Cells Or W/ Gmcsf In AdjuvantNational Center For Research Resources1999–2002
Pulsed Dendritic Cells For Induction Of Antitumor Immunity In Melanoma PatientsNational Center For Research Resources1998–2002
Core--Tissue Procurement FacilityNational Cancer Institute1995–2002
Autologous Melanoma Cell Vaccine With Gmcsf And IL2National Cancer Institute2000–2001
Peptide Based Vaccines For Stage IV MelanomaNational Cancer Institute1998–2000
HLA-A2 Associated Peptide Epitopes For CTL On MelanomaNational Cancer Institute1997–1999
HLA-A2 Associated Peptide Epitopes For CTL On MelanomaNational Cancer Institute1992–1996